India Biomarker Atlas
The India Biomarker Atlas is a future product concept: a governed collection of experimental and clinical-context evidence for populations underrepresented in many global reference datasets. It is not currently available, licensed, or populated through Apollo.
Why build it through programmable experiments
A useful atlas needs more than a large table of variants. It needs reproducible measurements, interpretable cohort definitions, clear consent scope, and provenance linking each result to how it was generated. The autonomous lab contributes repeatability; clinical collaborators contribute legitimate context and governance.
Standardized assays
Comparable measurements produced through versioned methods and controls.
Population relevance
Research questions designed around Indian and South Asian diversity rather than treating it as an afterthought.
Longitudinal context
Where permitted, link experimental findings to outcomes without exposing raw identities.
Consent-aware provenance
Every export tied to permitted purpose, source, method, quality, and governance metadata.
Illustrative development path
| Stage | Scope | Exit criterion |
|---|---|---|
| Pilot | One disease area, one institution, one assay family | Ethics approval, signed agreement, reproducible data contract |
| Reference cohort | Multiple sites or cohorts using the same measurement standard | External scientific review and documented representativeness |
| Research product | Governed access for qualified academic and industry users | Validated privacy, licensing, support, and withdrawal processes |
| Expansion | Additional diseases, assays, and APAC collaborators | Evidence of scientific utility and sustainable economics |
Commercial model
No price is published because the asset does not yet exist. Potential models include sponsored cohort creation, governed research access, co-development, and institution-approved licensing. Economics would be negotiated with data and clinical partners before any offer is made.